This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
by Zacks Equity Research
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead
by Zacks Equity Research
Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead
Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
by Zacks Equity Research
Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.
Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study
by Zacks Equity Research
Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.
Lessons from a Legendary Value Investor
by Tracey Ryniec
Value investors are rare. Find out what it takes to be one and how to find value stocks from one of the greats.
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
by Zacks Equity Research
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years
Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit
by Zacks Equity Research
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
Shire, Shionogi File NDA for Intuniv for Adults in Japan
by Zacks Equity Research
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech
by Zacks Equity Research
Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
by Zacks Equity Research
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
by Zacks Equity Research
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
by Zacks Equity Research
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
by Zacks Equity Research
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
by Zacks Equity Research
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.